Overview


According to FutureWise analysis the market for Neurological Disorder Drugs is expected to reach US$ 141.44 billion by 2031 at a CAGR of 6.10%.

A neurological illness occurs when any portion of the brain or nervous system malfunctions, resulting in physical or psychological symptoms. Congenital neurological abnormalities are those that appear during the early stages of embryo development and can be detected at birth. Traumatic brain injuries, immunological diseases, postnatal injections, spinal cord injuries, neoplasia, and exposure to ambient chemicals or poisons, among other things, cause acquired neurological disorders after birth. Multiple types of brain injuries and neurological diseases are among the leading causes of death worldwide. The neurological condition is frequently associated with dysfunction in any part of the brain or nervous system, manifesting both physically and psychologically. Only a few neurological illnesses are hereditable, and they manifest throughout the embryonic development of the kid and can be diagnosed at birth. Due to immunological diseases, neoplasms, postnatal injections, spinal cord injuries, traumatic brain injuries, and vulnerability to environmental pollutants, among other things, neurological illnesses arise after delivery. Furthermore, the drug possibilities are purely based on the patient's neurological state. These medications aid in the treatment of neurological illnesses, the reduction of symptoms, and the improvement of life expectancy. Corticosteroids are widely used in neurological medications, and they have been shown to be effective in treating multiple sclerosis and lowering rash. Anticholinergic, antiepileptic, antipsychotic, hypnotic and sedative, analgesics, antihypertensive, anticoagulants, and others are the pharmacological classes that make up the global neurological disorder pharmaceuticals market. Epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular illnesses, and other neurological disorders can all be treated with medications. For the treatment of neurologic illnesses, there are over 450 different drugs available.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Neurological Disorder Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Neurological Disorder Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

The key driving factors assisting the growth of these two segments are the rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to the presence of a strong drug pipeline is expected to impact the market share of traditional drug treatments and further boost the overall growth of this market. Rising research and development activities in the field of neurology have been the key driver for the neurological diseases treatment market and are expected to fuel its growth throughout the forecast period.

  • Amgen Inc
  • UCB S.A
  • Neurocrine Biosciences, Inc
  • Pfizer Inc
  • Biogen Inc
  • Teva Pharmaceutical Industries Ltd
  • AcelRx Pharmaceuticals, Inc
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc
  • Adamas Pharmaceuticals, Inc
  • BioMarin Pharmaceutical Inc
  • Otsuka America Pharmaceutical, Inc
  • AstraZeneca plc
  • Novartis International AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Antipsychotic
  • Antiepileptic
  • Anticholinergic
  • Analgesics
  • Hypnotic and Sedative
  • Anticoagulants
  • Antihypertensive

By Disease Type

  • Epilepsy
  • Parkinson’s disease
  • Alzheimer’s disease
  • Cerebrovascular disease
  • Multiple Sclerosis
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Neurological Disorder Drugs Market By Drug Type, By Disease Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neurological Disorder Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neurological Disorder Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neurological Disorder Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neurological Disorder Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antipsychotic
        2. Antiepileptic
        3. Anticholinergic
        4. Analgesics
        5. Hypnotic and Sedative
        6. Anticoagulants
        7. Antihypertensive

  • 8.   Neurological Disorder Drugs Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Epilepsy
        2. Parkinson’s disease
        3. Alzheimer’s disease
        4. Cerebrovascular disease
        5. Multiple Sclerosis
        6. Others

  • 9.   Neurological Disorder Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Online pharmacies

  • 10.   North America Neurological Disorder Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Neurological Disorder Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Neurological Disorder Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Neurological Disorder Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. UCB S.A
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Neurocrine Biosciences, Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Biogen Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Teva Pharmaceutical Industries Ltd
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AcelRx Pharmaceuticals, Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eli Lilly and Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Ionis Pharmaceuticals, Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Adamas Pharmaceuticals, Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. BioMarin Pharmaceutical Inc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Otsuka America Pharmaceutical, Inc
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. AstraZeneca plc
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Novartis International AG
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients